It has been reported that trastuzumab resistant cells exhibit enhanced glycolysis phenotype, and glycolytic restraint is able to sensitize trastuzumab resistant HER2+ breast cancers to trastuzumab treatment (303). Here, ERBB2 is linked to breast cancer.